01671nas a2200301   4500000000100000008004100001653001200042653002200054653002200076653001200098653003900110100001300149700001300162700001400175700001100189700001300200700001400213700001200227700001200239700001200251700001200263245011700275856007600392300001000468490000700478520087000485022001401355       2017                            d10aleprosy10aImmunoprophylaxis10aImmunotherapeutic10aVaccine10aMycobacterium indicus pranii (MIP)1 aTalwar G1 aGupta JC1 aMustafa A1 aKar HK1 aKatoch K1 aParida SK1 aReddi P1 aAhmed N1 aSaini V1 aGupta S00aDevelopment of a potent invigorator of immune responses endowed with both preventive and therapeutic properties.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422320/pdf/btt-11-055.pdf  a55-630 v113 a<p>This article reviews briefly the making of an immunoprophylactic-cum-immunotherapeutic vaccine against leprosy. The vaccine is based on cultivable, heat-killed atypical mycobacteria, whose gene sequence is now known. It has been named Mycobacterium indicus pranii. It has received the approval of the Drug Controller General of India and the US Food and Drug Administration. Besides leprosy, M. indicus pranii has found utility in the treatment of category II ("difficult to treat") tuberculosis. It also heals ugly anogenital warts. It has preventive and therapeutic action against SP2/O myelomas. It is proving to be a potent adjuvant for enhancing antibody titers of a recombinant vaccine against human chorionic gonadotropin, with the potential of preventing pregnancy without derangement of ovulation and menstrual regularity in sexually active women.</p>
  a1177-5475